Under the leadership of our CEO Hannes Berger, Dr. Schär ended 2024 with an outstanding result: our global turnover reached USD 676 million, an increase of 11% compared to the previous year. This achievement is the result of a successful strategy and a clear vision, which allow us to continue to grow, shaping the future of gluten-free and special nutrition and responding even more closely to the needs of our consumers worldwide.
International expansion and the reinforcement of certain strategic markets played a key role in achieving these results.
- In the Nordic countries, with the acquisition of Hero’s gluten-free business, we secured a significant market share;
- In Spain, we further expanded our plant in Alagón (Zaragoza), adding a new production line dedicated to both sweet and savory bakery products, which will be marketed throughout Europe. This also enabled us to grow our workforce, with the addition of more than 30 new employees in the production area;
- In the United States, we centralized operations in Swedesboro (New Jersey), and enhanced the facility dedicated to the production of gluten- and soy-free bread and rolls.

“In an ever-changing market, our priority is to consolidate our core brand by strengthening our position in current markets and expanding into new strategic areas. We aim for dynamic growth through investments in innovation, digitalization, and sustainability. Our goal is to offer consumers increasingly advanced nutritional solutions, expanding our global presence and maintaining the high standards of excellence that set us apart from other players in the market” - our CEO Hannes Berger says.
For us, growth is not just about numbers; it’s also about investing in the development of solutions the meet the increasingly precise needs of people with specific nutritional requirements. The launch of our new Mikara brand reflects this commitment. Mikara Shake, available since December 2024, is a food for special medical purposes designed to support patients with rheumatoid arthritis in their daily dietary management. This milestone marks an important step in the evolution of our offering, and opens up new growth opportunities in the special nutrition market.
Our business success is complemented by our commitment to seeding a better world. In 2025, we will publish our second Sustainability Report, showcasing the progress made in 2023-2024 and highlighting the process of transformation towards sustainability that we have embarked upon.